Evaluation Of New Onset Postoperative Atrial Fibrillation

NCT ID: NCT01247974

Last Updated: 2023-07-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

439 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, prospective, randomized and controlled clinical trial comparing the safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation by circumferentially reconstructing the normal pericardial anatomy following isolated, first-time, CABG procedures compared to subjects that do not undergo pericardial closure. This trial will be conducted at up to 20 clinical sites in the U.S.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this prospective clinical trial is to demonstrate the safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation by circumferentially reconstructing the normal pericardial anatomy following isolated, first-time, coronary artery bypass grafting (CABG) procedures as compared to subjects who did not undergo pericardial closure. Safety will be established by demonstrating that the composite clinical event rate for the ECM treatment group is not worse than the control group that did not undergo pericardial closure. The efficacy will be established by demonstrating a reduced incidence of new onset postoperative atrial fibrillation in the ECM treatment group as compared to the control group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation New Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CorMatrix ECM for Pericardial Closure

Pericardial closure with CorMatrix ECM

Group Type EXPERIMENTAL

CorMatrix ECM for Pericardial Closure

Intervention Type DEVICE

Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure

Control

No Pericardial Closure

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CorMatrix ECM for Pericardial Closure

Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is 18 years of age or older
* This cardiac operation is the subject's first or primary cardiac operation
* The subject must be undergoing an isolated CABG procedure using a median sternotomy approach
* The subject must possess the ability to provide written Informed Consent
* The subject must express a willingness to fulfill all of the expected requirements of this clinical protocol

Exclusion Criteria

* Prior history of atrial fibrillation
* Prior history of open heart surgery
* Prior history of pericarditis
* Prior history of anti-arrhythmia drug treatment (e.g., amiodarone, dronedarone or sotalol) in the past six months
* The subject has an implantable cardiac device (i.e., cardiac resynchronization therapy devices with and without defibrillator capabilities (CRTs and CRT-Ds), implantable cardioverter-defibrillators (ICD) and pacemakers)
* Concomitant procedure planned
* In the investigator's opinion, the subject may require prophylactic treatment with anti-arrhythmia drugs or temporary pacing postoperatively
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Elutia Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marc Gerdisch, M.D.

Role: PRINCIPAL_INVESTIGATOR

St. Francis Heart Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Trinity Medical Center

Birmingham, Alabama, United States

Site Status

Southeast Alabama Medical Center

Dothan, Alabama, United States

Site Status

Mobile Infirmary Medical Center

Mobile, Alabama, United States

Site Status

Providence Hospital

Mobile, Alabama, United States

Site Status

Saint Agnes Medical Center

Fresno, California, United States

Site Status

Stanford University School of Medicine

Stanford, California, United States

Site Status

St. Vincent's Hospital

Jacksonville, Florida, United States

Site Status

Florida Hospital

Orlando, Florida, United States

Site Status

Advocate Christ Medical Center

Oak Lawn, Illinois, United States

Site Status

Saint Francis Heart Center

Indianapolis, Indiana, United States

Site Status

St. Luke's Hospital

Kansas City, Missouri, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

The Ohio State University Medical Center

Columbus, Ohio, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Baptist Memorial Hospital

Memphis, Tennessee, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08-PR-1006

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BoxX-NoAF Clinical Trial
NCT06989775 RECRUITING NA